Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Definition and Independent Validation of a Proteomic-Classifier in Ovarian Cancer

Title: Definition and Independent Validation of a Proteomic-Classifier in Ovarian Cancer
Authors: Kasimir-Bauer, Sabine; Roder, Joanna; Obermayr, Eva; Mahner, Sven; Vergote, Ignace; Loverix, Liselore; Braicu, Elena; Sehouli, Jalid; Concin, Nicole; Kimmig, Rainer; Net, Lelia; Roder, Heinrich; Zeillinger, Robert; Aust, Stefanie
Source: ISSN:2072-6694 ; Cancers, vol. 12 (9), Art.No. ARTN 2519.
Publisher Information: Multidisciplinary Digital Publishing Institute (MDPI)
Publication Year: 2020
Subject Terms: Science & Technology; Life Sciences & Biomedicine; Oncology; ovarian cancer; proteomics; mass spectrometry; survival; MULTIVARIATE INDEX ASSAY; MASS-SPECTROMETRY; BIOMARKER; ERLOTINIB; MULTICENTER; SIGNATURE; DISCOVERY; DISEASE; 1112 Oncology and Carcinogenesis; 3211 Oncology and carcinogenesis
Description: Mass-spectrometry-based analyses have identified a variety of candidate protein biomarkers that might be crucial for epithelial ovarian cancer (EOC) development and therapy response. Comprehensive validation studies of the biological and clinical implications of proteomics are needed to advance them toward clinical use. Using the Deep MALDI method of mass spectrometry, we developed and independently validated (development cohort: n = 199, validation cohort: n = 135) a blood-based proteomic classifier, stratifying EOC patients into good and poor survival groups. We also determined an age dependency of the prognostic performance of this classifier, and our protein set enrichment analysis showed that the good and poor proteomic phenotypes were associated with, respectively, lower and higher levels of complement activation, inflammatory response, and acute phase reactants. This work highlights that, just like molecular markers of the tumor itself, the systemic condition of a patient (partly reflected in proteomic patterns) also influences survival and therapy response in a subset of ovarian cancer patients and could therefore be integrated into future processes of therapy planning. ; status: Published
Document Type: article in journal/newspaper
File Description: application/pdf
Language: English
Relation: https://lirias.kuleuven.be/handle/123456789/660082; https://doi.org/10.3390/cancers12092519; https://pubmed.ncbi.nlm.nih.gov/32899818
DOI: 10.3390/cancers12092519
Availability: https://lirias.kuleuven.be/handle/123456789/660082; https://lirias.kuleuven.be/retrieve/78e95e54-3ec7-4887-93dd-7e88192e83be; https://doi.org/10.3390/cancers12092519; https://pubmed.ncbi.nlm.nih.gov/32899818
Rights: info:eu-repo/semantics/openAccess ; public
Accession Number: edsbas.CC7CBAE8
Database: BASE